Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zenon fixed-dose combination versus rosuvastatin uptitration in primary hypercholesterolemia
2016-004556-30Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ezetimibe and rosuvastatin in hypercholesterolemia (5 arms), sponsored by Sanofi. Primary endpoint: Percent change in calculated low-density lipoprotein cholesterol. Started Jul 2018; status: completed.
02
Drugs
ezetimiberosuvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2016-004556-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004556-30.